A multicentre, prospective, observational cohort study to assess the effects of vildagliptin relative to sulphonylurea as dual therapy with metformin (or as monotherapy*) in Muslim patients with type 2 diabetes fasting during Ramadanâ?? - VIRTUE

ovartis HealthCare private Limited0 个研究点目标入组 1,000 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•The study includes patients who meet the following criteria:
•1.Give written informed consent before any data is collected
•2.18 years of age or older
•3.Diagnosed with T2DM at least 12 months prior to the start of Ramadan fasting
•4.Treated, for at least 4 weeks but not more than 3 years before fasting commences, with either vildagliptin as dual therapy with metformin (or vildagliptin as monotherapy) OR sulphonylurea as dual therapy with metformin (or sulphonylurea as monotherapy)
•5.Plan to fast during Ramadan
•6.Have HbA1c <= 8.5% (as measured within 6 weeks prior to entry into the study)

•1.Contraindications appearing in the local approved prescribing information for the prescribed medication
•2.Use of any investigational drugs at the time of enrolment, or within 30 days or 5 half-lives of enrolment, whichever is longer
•3.Patients who require three or more oral anti-diabetes therapies at time of study entry
•4.Patients who are using insulin at the time of study entry.

发起方

ovartis HealthCare private Limited